O. Ortega

Recombinant dengue 2 virus NS3 protein conserves structural antigenic and immunological properties relevant for dengue vaccine design

M. Guzmán, R. Mohana-Borges, A. B. Pérez, 2014, Virus Genes.

Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers

C. Broder, J. Powers, A. Snow, 2021, medRxiv.

A new tetravalent Dengue vaccine formulation based on four chimeric envelope domain III-capsid proteins induces a functional immune response in mice and non-human primates

M. Guzmán, L. Lazo, G. Guillén, 2017 .